Tiragolumab

BioAge Labs halted azelaprag trials due to safety concerns; Biohaven's taldefgrobep alfa showed muscle-preserving effects in failed SMA trial, prompting obesity study. Roche's tiragolumab failed phase 3, dimming anti-TIGIT drug prospects; Gilead/Arcus' domvanalimab shows promise. AbbVie's emraclidine failed schizophrenia trials, impacting market cap. Cassava's simufilam failed Alzheimer's phase 3, amid SEC investigation.

Roche acquires Poseida Therapeutics for up to $1.5B, expanding into CAR-T therapies. U.S. overdose deaths decline by 14.5% to 97,000 over 12 months. Arrowhead Pharmaceuticals licenses programs to Sarepta Therapeutics for $500M upfront and $325M in equity. Recordati and Angelini Pharma consider merger to form Europe's largest generics group. FDA approves BridgeBio's heart drug for transthyretin amyloidosis, challenging Pfizer's tafamidis. Novo Holdings expected to receive EU approval for $16.5B acquisition of Catalent Pharma Solutions. Amgen's obesity drug MariTide shows 20% weight loss in Phase II. Anavex Life Sciences submits MAA to EMA for Alzheimer's treatment. Biohaven's muscle drug fails in SMA study. embecta reports strong revenues of $1.12B, discontinues insulin patch pump. Axsome Therapeutics reports positive Phase 3 results for narcolepsy drug AXS-12. Kronos Bio to lay off 83% of workforce. PTC Therapeutics sells Rare Pediatric Disease Priority Review Voucher for $150M. EMA launches medicine shortages monitoring platform. Alector lays off 41 employees after Alzheimer's drug AL002 fails. Grifols seeks to refinance €1.4B in debt. Roche's cancer drug tiragolumab fails Phase 3 trial.

FDA accepts BLA for belantamab mafodotin–based combos in R/R myeloma; approves oral solution of imatinib for certain leukemias and other cancers; capivasertib plus abiraterone/ADT improves rPFS in PTEN-deficient mHSPC; Pancreatic Cancer Awareness Month highlights growing incidence and treatment advances; tiragolumab plus atezolizumab fails to meet OS end point in PD-L1–high NSCLC.

Roche to acquire Poseida Therapeutics for $1 billion. Merck, AstraZeneca, and Novartis see success in new drug studies. Novartis' Kisqali approved for broader breast cancer treatment in EU.

Genentech reports SKYSCRAPER-01 study did not reach primary endpoint of overall survival in Phase III trial evaluating tiragolumab plus Tecentriq vs. Tecentriq alone for PD-L1-high NSCLC. Safety profile remained consistent, with no new signals identified. Detailed data to be presented in 2025.

Roche's experimental cancer treatment, tiragolumab, combined with Tecentriq, failed to improve survival in a major lung cancer study, raising doubts about its target protein TIGIT.

Roche's SKYSCRAPER-01 phase III study did not meet the primary endpoint of overall survival for tiragolumab plus Tecentriq vs. Tecentriq alone in PD-L1-high NSCLC patients. Safety profile remained consistent, with no new signals. Data to be presented in 2025. Roche continues to review its study programs.

Roche's Phase 3 trial SKYSCRAPER-01 showed tiragolumab did not improve survival in advanced lung cancer, failing to meet primary goals. Despite earlier promising data, final analysis indicated no sustained benefit. Roche will review tiragolumab's development, while other companies continue TIGIT drug research, hoping for breakthroughs.

The phase 3 SKYSCRAPER-01 study did not meet the primary end point of overall survival (OS) for the combination of tiragolumab and atezolizumab vs atezolizumab alone in PD-L1-high, locally advanced or metastatic non–small cell lung cancer (NSCLC). The combination's safety profile remained consistent with no new signals. Full findings will be presented in 2025, and Roche will evaluate ongoing studies to determine necessary adjustments.

Tiragolumab with atezolizumab failed to improve overall survival in PD-L1–high, locally advanced or metastatic NSCLC patients compared to atezolizumab alone in the SKYSCRAPER-01 study. No new safety signals were identified, and more data will be presented in 2025.